OncoMatch/Clinical Trials/NCT03011684
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
Is NCT03011684 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Tamoxifen and Letrozole for infertility.
Treatment: Tamoxifen · Letrozole — Latrogenic infertility as a result of cancer treatment has a profound effect on long-term quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to cancer treatment has been associated with improved quality of life, with a potential ability to reduce long-term decision-related regret in cancer survivors. Though letrozole plus gonadotropin and and tamoxifen plus gonadotropin are currently routinely used worldwide in ovarian stimulation cycles for fertility preservation in patients with estrogen-receptor-positive breast cancer, it is not clear which of the two might lead to improved oocyte yield. Improved knowledge about the efficacy of these medications, with regard to oocyte yield, has the potential to significantly improve quality of life in reproductive-age breast cancer survivors.
Check if I qualifyExtracted eligibility criteria
Disease stage
Excluded: Stage IV
Prior therapy
Cannot have received: chemotherapy
Chemotherapy has already commenced or been completed
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California at San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify